

# Birmingham Centre for Clinical Trials

The Birmingham Centre for Clinical Trials conducts trials at a scale, quality and pace that only decades of experience can achieve. For 40 years, clinical trials at the University of Birmingham have driven forward translational research in a vast array of therapeutic areas across drugs, devices and diagnostics. From running the UK's paediatric cancer trials unit and the National Lung Cancer Matrix Trial, to delivering diagnostic test evaluation studies such as eGFR-c, few European trials units can match our size or our capabilities.

The Birmingham Centre for Clinical Trials is a single gateway for accessing leading academic and clinical expertise in any therapeutic area. This critical mass of knowledge in one of the UK's largest healthcare clusters enables us to deliver trials of world-leading quality, international reach and exceptional efficiency.

## Key features

- 40-year track record of delivering trials and trial expertise at the University of Birmingham
- Outstanding national and international leadership in clinical research
- One of Europe's largest clinical trials units for cancer research
- The UK's paediatric cancer trials unit
- Cutting-edge programmes to accelerate trial development and implementation in blood cancer, arthritis and stem cell transplant – with potential for more
- Rapid patient recruitment
- Novel trial designs and novel statistical approaches

## How we can collaborate


There are various levels at which you can collaborate with us on a clinical trial – as shown below.

Historically, investigator-initiated trials have been the University's usual model of collaboration – and this will remain the bulk of our work. However, we are open to working on industry-sponsored trials, providing the University retains the academic freedom to apply the expertise on which our reputation is built.

## Our capabilities

- The expertise to work in any therapeutic area
- A successful track record from pre-clinical studies and early trial design, through early and late phase trials, to diagnostic test evaluation
- Operation of truly global, multi-centre studies at scale
- Trials conducted across a wide range of diseases and age groups, and in primary, secondary, tertiary and community settings
- Trials in drugs, devices and diagnostics

## Levels of collaboration



# Birmingham Centre for Clinical Trials



## Key projects

We have over 200 trials running at any given time. Here are just a few which illustrate the breadth of our experience.

**National Lung Cancer Matrix Trial:** The world's largest precision medicine trial in non-small cell lung cancer, testing a wide range of therapies tailored specifically to target key genetic changes in cancer cells. The trial is recruiting more than 600 patients across 20 sites nationwide, with a further seven planned. Multiple pharmaceutical companies and several other partners are involved in this ground-breaking study. [birmingham.ac.uk/lung-matrix](http://birmingham.ac.uk/lung-matrix)

**eGFR-c – Kidney:** A diagnostic test evaluation study recruiting 1,320 patients from hospital clinics and GP practices through six major UK centres. The aim is to evaluate the performance of various existing and novel glomerular filtration rate (GFR) equations in assessing and monitoring measured GFR in patients with moderate chronic kidney disease. GFR is an important measure of kidney function. The trial is funded by the NIHR Health Technology Assessment Programme. [birmingham.ac.uk/egfr-c](http://birmingham.ac.uk/egfr-c)

**BEACON – Paediatric cancer:** An international multi-centre trial testing six therapy combinations in a rare paediatric cancer, neuroblastoma. BEACON is recruiting 160 patients from 41 sites in 11 European countries. Partners include Cancer Research UK, Roche and Imagine for Margo. [birmingham.ac.uk/beacon](http://birmingham.ac.uk/beacon)

**VITTAL – Liver transplant:** Birmingham hosts the largest medical device cluster in the UK. The VITTAL trial uses the novel technique of normothermic machine liver perfusion (NMLP) to establish the suitability of livers that have been declined by all UK liver transplant centres, and transplants the liver if the NMLP device indicates it is suitable. The trial uses the OrganOx metra® device manufactured by Organox Ltd. [clinicaltrials.gov/ct2/show/NCT02740608](https://clinicaltrials.gov/ct2/show/NCT02740608)

**ROSSINI-2 – Abdominal surgery:** A multi-arm, multi-stage (MAMS) pragmatic trial recruiting 6,600 patients from at least 70 UK hospitals. The trial assesses whether specific interventions during abdominal surgery, alone or in combination, result in decreased rates of surgical site infection after the operation. It is funded by the NIHR Health Technology Assessment Programme. [bit.ly/2LcgqVI](https://bit.ly/2LcgqVI)

## Getting in touch

To learn more about engaging with the University please contact the Business Engagement team:

**Email:** [businessteam@contacts.bham.ac.uk](mailto:businessteam@contacts.bham.ac.uk)

**Website:** [www.birmingham.ac.uk/partners](http://www.birmingham.ac.uk/partners)

**Twitter:** @UoBBWB

Designed and printed by

UNIVERSITY OF  
BIRMINGHAM

creativemedia